Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 9/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20454407 | 1.00 | CHEK2 (0.43) | CHEK2CACNA1HIDO1HTR2BCACNA1G | |
| SCHEMBL9028459 | 0.76 | F10 (0.55) | CHEK2MMP2MMP13 | |
| SCHEMBL20454715 | 0.75 | RORC (0.48) | — | |
| SCHEMBL22533832 | 0.73 | MMP2 (0.50) | CHEK2MMP2MMP13 | |
| SCHEMBL28699433 | 0.72 | CACNA1H (0.53) | CHEK2CACNA1HIDO1HTR2BCACNA1G | |
| SCHEMBL9569971 | 0.72 | APEX1 (0.45) | CHEK2MMP2MMP13 | |
| SCHEMBL9598107 | 0.72 | APEX1 (0.45) | CHEK2MMP2MMP13 | |
| SCHEMBL20454631 | 0.71 | RORC (0.53) | — | |
| SCHEMBL28462815 | 0.71 | SMN1; SMN2 (0.58) | CHEK2MMP2MMP13 | |
| SCHEMBL29488675 | 0.71 | SMN1; SMN2 (0.58) | CHEK2MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICAL, LLC | 2021-09-30 | — | — | US | disclosed |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | RORB, RORC, RORA | CHEK2 4663/4885CACNA1H 3901/4885IDO1 6/4885 |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | CHEK2 4757/4885CACNA1H 4197/4885IDO1 735/4885 |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | CHEK2 4757/4885CACNA1H 4197/4885IDO1 735/4885 |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | RORC, RORB, RORA | CHEK2 4563/4885CACNA1H 4183/4885IDO1 97/4885 |
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | CHEK2 4384/4885CACNA1H 3837/4885IDO1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.